Beam Therapeutics Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Beam Therapeutics is a biotechnology company developing precision genetic medicines based primarily on base-editing technology, with programs in hematology, immunology/oncology and genetic diseases. The filing covers the three months ended March 31, 2023, and was filed on May 10, 2023. The company has not generated product revenue and all programs remain preclinical or early clinical stage.
Financial performance, liquidity and capital structure
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| License and collaboration revenue | $24.2 million | $8.4 million | +$15.8 million |
| Research and development expense | $99.6 million | $65.4 million | +$34.2 million |
| General and administrative expense | $23.5 million | $19.2 million | +$4.2 million |
| Loss from operations | $(98.9) million | $(76.2) million | $(22.7) million |
| Net loss | $(96.5) million | $(69.2) million | $(27.2) million |
| Basic and diluted loss per share | $(1.33) | $(1.01) | $(0.32) |
| Net cash used in operating activities | $(109.8) million | $218.5 million | $(328.3) million |
- Derived operating margin was approximately negative 409%, compared with approximately negative 904% in Q1 2022; derived net margin was approximately negative 399%, compared with approximately negative 821%.
- Cash and cash equivalents were $249.8 million, and marketable securities were $809.7 million, for approximately $1.06 billion of immediately reported cash and marketable securities. Including restricted cash, total cash, cash equivalents and restricted cash was $259.6 million.
- Total assets were $1.33 billion and total stockholders’ equity was $761.5 million at March 31, 2023.
- Equipment financing liabilities totaled $2.4 million. Lease liabilities totaled approximately $176.5 million; the filing does not identify conventional funded debt as a material financing source.
- Operating cash use reflected the $96.5 million net loss, a $23.7 million reduction in deferred revenue and working-capital uses. Q1 2022 operating cash flow benefited from collection of the $300.0 million Pfizer upfront payment.
- Financing activities provided $98.4 million, primarily from $94.0 million of net equity offering proceeds, $3.4 million from option exercises and $1.7 million from the employee stock purchase plan.
Material changes versus the prior comparable period
- Revenue increased primarily because of higher revenue recognized under the Pfizer, Apellis and Orbital collaborations.
- Research and development expense increased 52%, driven by manufacturing and clinical expenses for BEAM-101 and BEAM-201, IND-enabling work for BEAM-301 and BEAM-302, animal studies for the lipid nanoparticle platform, increased staffing and facility costs.
- Research and development headcount increased from 321 to 429 employees, while general and administrative headcount increased from 73 to 94.
- Interest and other income increased to $10.0 million from $0.6 million, primarily because of higher market interest rates.
- Mark-to-market losses on equity investments increased to $12.8 million from $7.7 million, including a $10.1 million loss on Prime Medicine and a $2.7 million loss on Verve Therapeutics.
- Fair-value gains on Harvard and Broad success-payment liabilities declined to $5.6 million from $13.6 million. The liabilities were $12.7 million at March 31, 2023, down from $18.3 million at year-end 2022.
- The company issued 2.43 million shares through its at-the-market offering for $93.8 million of net proceeds, increasing shares outstanding to 74.4 million at March 31, 2023 from 71.3 million at December 31, 2022.
Guidance, outlook, commentary and risks
- Management expects cash, cash equivalents and marketable securities at March 31, 2023 to fund current and planned operations and capital expenditures for at least the next 12 months from the financial statement issuance date, but expects continuing operating losses and negative operating cash flow.
- Management expects to require additional capital and may use equity or debt financings, collaborations, strategic alliances and licensing arrangements. No committed external source of capital exists.
- The BEACON trial for BEAM-101 had five active sites. The first enrolled patient withdrew for personal, non-medical reasons before treatment; two additional patients were in the sentinel cohort. Management expected to complete sentinel enrollment and begin expansion enrollment in 2023, with data from multiple patients planned for 2024.
- Management expected to dose the first patient in the BEAM-201 Phase 1/2 trial by mid-2023.
- Regulatory applications were planned for BEAM-301 by late 2023 or early 2024 and BEAM-302 in early 2024.
- The company’s 100,000-square-foot North Carolina manufacturing facility became operational in the first quarter of 2023, with cGMP operations expected to begin in late 2023. Execution, qualification and operating costs remain significant risks.
- A research institution alleged breach of confidentiality, trade-secret misappropriation and related claims involving technology associated with BEAM-102 and BEAM-302. Beam accrued $3.4 million, equal to an offered settlement amount; the offer was rejected, no complaint had been filed, and the ultimate outcome could be materially different.
- Key risks include clinical-trial enrollment and treatment delays, uncertain safety and efficacy of base-editing therapies, regulatory approval risk, evolving third-party intellectual-property claims, reliance on contract manufacturers and suppliers, supply constraints for nonhuman primates, and the need for additional financing.
- Management stated that COVID-19 did not materially affect Q1 2023 results, but future public-health, supply-chain, geopolitical and macroeconomic disruptions could adversely affect operations.
Most important facts for investors to verify
- Whether the reported liquidity runway remains adequate as clinical, manufacturing and platform spending increases.
- Progress, enrollment, treatment and safety data from the BEACON trial and the timing of BEAM-201 dosing.
- Whether BEAM-301 and BEAM-302 regulatory submissions occur on the stated timelines.
- Progress toward cGMP qualification and operational readiness of the North Carolina manufacturing facility.
- The sustainability and timing of collaboration revenue, particularly the remaining Pfizer, Apellis and Orbital deferred revenue balances.
- The resolution and potential financial exposure related to the research institution’s confidentiality and trade-secret allegations.
- Potential dilution from additional ATM sales, equity financing, stock compensation and Guide-related milestone obligations.
- Relevant patent disputes, licensing requirements and third-party intellectual-property claims affecting base editing, delivery technology and product candidates.